



RESEARCH ARTICLE

**REVISED** Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development [version 2; peer review: 2 approved]

Iman Almansour , Rahaf Alfares , Halah Aljofi

Epidemic Diseases Department-Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Eastern Region, P.O.Box 1982, Dammam 31441, Saudi Arabia

**v2** First published: 10 Oct 2018, 7:1624 (<https://doi.org/10.12688/f1000research.16454.1>)  
 Latest published: 27 Jun 2019, 7:1624 (<https://doi.org/10.12688/f1000research.16454.2>)

**Abstract**

**Background:** Cases of the re-emergence of Zika virus in 2015 were associated with severe neurologic complications, including Guillien-Barre syndrome in adults and congenital Zika syndrome in newborns. The major structural determinant of immunity to the Zika virus is the E protein. Although B-cell epitopes of Zika E protein were recently identified, data regarding epitope variations among Zika strains in pre-epidemic and epidemic periods are lacking.

**Methods:** Here, we conducted systematic bioinformatics analyses of Zika strains isolated between 1968 and 2017. Multiple sequence alignment of E protein as well as B-cell epitopes annotations were performed. In addition, homology-based approach was utilized to construct three-dimensional structures of monomeric E glycoproteins to annotate epitope variations. Lastly, prediction of N-glycosylation patterns and prediction of protein stability upon mutations were also investigated.

**Results:** Our analyses indicates that epitopes recognized by human mAbs ZIKV-117, ZIKV-15, and ZIKV-19 were highly conserved, suggesting as attractive targets for the development of vaccines and immunotherapeutics directed against diverse Zika strains. In addition, the epitope recognized by ZIKV-E-2A10G6 mAb derived from immunized mice was mostly conserved across Zika strains.

**Conclusions:** Our data provide new insights regarding antigenic similarities between Zika strains circulating worldwide. These data are essential for understanding the impact of evolution on antigenic cross-reactivity between Zika lineages and strains. Further *in-vitro* analyses are needed to determine how mutations at predefined epitopes could impact the development of vaccines that can effectively neutralize Zika viruses.

**Keywords**

Antibody, Bioinformatics, Envelope, Epitope, Homology Modeling, Neutralizing Antibodies, Vaccine, Zika


**Open Peer Review**

**Reviewer Status**

	Invited Reviewers	
	1	2
<b>REVISED</b>		
<b>version 2</b>	report	
published		
27 Jun 2019		
	↑	
<b>version 1</b>	?	
published	report	report
10 Oct 2018		

- Meirong Jia**, Iowa State University, Ames, USA  
Department of Plant Biology, Davis, USA
- Sunil K Joshi** , University of Miami, Miami, USA  
University of Miami, Miami, USA

Any reports and responses or comments on the article can be found at the end of the article.



This article is included in the **Disease Outbreaks** gateway.



This article is included in the **Zika & Arbovirus Outbreaks** collection.

**Corresponding author:** Iman Almansour ([ikalmansour@iau.edu.sa](mailto:ikalmansour@iau.edu.sa))

**Author roles:** **Almansour I:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Alfares R:** Data Curation, Formal Analysis, Investigation, Writing – Review & Editing; **Aljofi H:** Data Curation, Formal Analysis, Funding Acquisition, Software, Visualization, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** The research was supported by Deanship of Scientific Research at Imam Abdulrahman Bin Faisal University [DSR 2017-376-IRMC].

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2019 Almansour I *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Almansour I, Alfares R and Aljofi H. **Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development [version 2; peer review: 2 approved]** F1000Research 2019, 7:1624 (<https://doi.org/10.12688/f1000research.16454.2>)

**First published:** 10 Oct 2018, 7:1624 (<https://doi.org/10.12688/f1000research.16454.1>)

**REVISED** Amendments from Version 1

The questions raised by the reviewer have been adequately addressed. Methods supplemented with additional information were added.

**Abstract:**

Correction of Antibody name ZIKV-119 to ZIKAV-19.

**Introduction:**

The release of PrM and E proteins of Zika was further elaborated.

**Methods:**

Additional details of protein stability prediction parameters were added. Likewise, further details of N-Glycosylation prediction were also provided.

**Results:**

Elaboration on factors affecting protein stability was added.

**See referee reports**

## Introduction

Zika is a positive-sense, enveloped, RNA virus of the *Flaviviridae* family<sup>1</sup>, which also includes dengue virus, West Nile virus (WNV), Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), and yellow fever virus (YFV)<sup>2</sup>. Zika was originally discovered in a rhesus monkey in 1947 in Uganda<sup>3</sup>, and the first case of spread to humans was reported in 1952<sup>4</sup>. Since that time, the virus has spread globally, with Zika outbreaks reported in Micronesia in 2007 and in the Pacific islands in 2013–2014<sup>5,6</sup>. A recent outbreak that began in Brazil in 2015 that eventually spread to countries in North America and the Caribbean<sup>7,8</sup>.

The Zika virus genome encodes three structural proteins (capsid [C], premembrane [PrM], and envelope [E]) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5)<sup>2</sup>. Similar to other flaviviruses, the structural proteins and viral genome form virions that assemble as immature particles at the endoplasmic reticulum of infected cells<sup>9</sup>. The immature particles are composed of 60 PrM/E protein heterodimers that protrude from the viral surface<sup>10</sup>. In the Golgi apparatus, PrM is cleaved by furin-like protease to produce mature M protein and Pr protein product<sup>2</sup>. After maturation, PrM and E are released and 90 E protein homodimers rearrange in a herringbone-like array forming mature Zika virus<sup>11,12</sup>.

The E protein is the major surface glycoprotein of flaviviruses and plays an essential role in virus attachment and fusion. Each E protein monomer consists of three domains: DI, DII, and DIII<sup>13</sup>, which undergo major rearrangements during the virus maturation cycle<sup>14,15</sup>. DI is a central beta-barrel domain; DII is a finger-like dimerization domain; and DIII is an immunoglobulin-like domain<sup>10,11</sup>. DI, which connects DII to DIII, is essential for the conformational changes required for viral entry into cells<sup>16</sup>. DII contains a fusion loop (FL) that interacts with the endosomal membrane, whereas DIII contains the receptor-binding site and is thus essential for attachment of virus particles to the host cell<sup>15,16</sup>. DIII also plays an essential role in mediating the fusion of virus particles with the endosomal membrane after endocytosis<sup>17</sup>.

The global spread of Zika virus in conjunction with the neurologic consequences of infection have increased the urgency of efforts to develop Zika vaccines and immunotherapeutics. Humoral immunity is the major source of host protection against flaviviruses, in which neutralizing antibodies play an important role in virus clearance<sup>18</sup>. Antibodies generated against the E protein have been shown to block the entry of viruses into host cells<sup>19</sup>. Previous attempts to map the antigenic epitopes of the Zika E protein utilized antibodies specific for other flaviviruses, such as dengue virus<sup>20–22</sup>. Recently, several B-cell antigenic epitopes within an individual E domain were identified in studies of antibodies isolated from Zika-virus infected patients<sup>23–25</sup> and Zika-vaccinated mice<sup>13,26,27</sup>.

Although antigenic epitopes of the E protein have been characterized based on maps prepared using Zika-specific antibodies, no systematic analyses of the specificity of Zika monoclonal antibodies (mAbs) for available Zika E protein sequences have been conducted. Such data are particularly important, as RNA viruses exhibit high mutation rates and can generate mutations that enable them to evade the host immune system. Importantly, the structural stability of E protein is a key factor for antibody binding. The amino acid substitutions and subsequent effects on structural stability and antibody binding can be performed by a homology based *in-silico* approach of the three-dimensional (3D) structure of E proteins. Hence, analyzing sequence data to annotate mutations at key residues and subsequent prediction of the effect of those mutations on protein structure stability is essential. Therefore, identifying novel amino acid mutations that are likely to contribute in the immune evasion is important.

In the present study, therefore, we extracted all of the available E protein sequences for Zika isolates obtained from 1968 to 2017 and constructed three-dimensional (3D) structures of E proteins from various Zika strains using homology modeling. We also investigated the patterns and conservation of E protein B-cell epitopes and assessed their structural stability upon mutation.

## Methods

### Data selection

Complete Zika polypeptide sequences for isolates identified between 1968 and 2017 were obtained from the National Center for Biotechnology Information (NCBI) [Zika resource](#)<sup>28</sup>. A total of 409 complete polypeptide sequences were retrieved, and duplicate sequences were removed. Multiple sequence alignment was performed using MUSCLE in the [Geneious tool](#), version 11.0, and the E protein region was extracted<sup>29</sup>. Lastly, MUSCLE alignment was performed for E protein sequences and duplicate E sequences were subsequently removed.

### Phylogenetic analysis

A phylogenetic tree for all unique Zika virus E protein sequences was constructed using the maximum-likelihood method with the [PhyML tool](#), version 3.0<sup>30</sup>, with 100 bootstrap replications. The tree applied an LG substitutional model to determine the divergence of E protein sequences. Lastly, the phylogenetic tree was edited using the [Figtree tool](#), version 1.4.3.

## Homology modeling

The **SWISS model**<sup>31</sup> server was used to generate 3D structures of the E proteins of Zika isolates identified in 1968, 2007, 2013, 2015, and 2016. Chain A of the E protein structure (PDB: 5GZN) was used as a template for homology modeling. The best homology model was selected based on global model quality estimate (GMQE) and Qmean statistics. Each homologous 3D structure was evaluated using Ramachandran plots prepared with **PROCHECK**<sup>32</sup>. Hydrogen bonds were added using **molprobt**<sup>33</sup>. Each model was subjected to energy minimization using the **ModRefiner** server described by Xu and Zhang<sup>34</sup>.

## Mapping of antigenic epitopes

E protein-specific antigenic epitopes of monoclonal antibodies (mAbs) isolated from Zika-virus infected humans and Zika immunized mice were retrieved from the **Immune Epitope Database** (IEDB)<sup>35</sup>, which is a free resource funded by the National Institute of Allergy and Infectious Diseases devoted to disseminating antigenic epitope data. Linear and conformational B-cell epitopes with positive major histocompatibility complex ligands were selected. B-cell epitope regions mapped with B-cell receptor (BCR)-positive neutralizing antibodies were also selected. Epitopes that mapped with screening peptides and did not elicit an immune response were removed. A total of 7 human and 10 mouse (from mice immunized with E protein) B-cell epitopes were identified. The identified epitopes were annotated against aligned E sequences as well as the 3D structures of monomeric E proteins using the **Chimera tool**<sup>36</sup>. Potential sites of *N*-glycosylation were predicted using **NetNglycan** 1.0 server<sup>37</sup>. Potential *N*-glycosylation sites were defined by the sequence Asp/X/Ser/Thr, where X represents any amino acid except Pro. The default threshold of >0.5 was used as predictor of *N*-glycosylated residue.

## Analysis of mutations on E protein stability

The effect of mutations on the stability of E protein was predicted using the **mutation cutoff scanning matrix** (mCSM)<sup>38</sup>, **site-directed mutator** (SDM)<sup>39</sup>, **DUET**<sup>40</sup>, and **I-Mutant 2.0**<sup>41</sup> tools. The mCSM is a machine-learning algorithm based on a 3D physiochemical environment, and the data are summarized as a graphical signature. The SDM is a statistical potential energy function based on the propensity of amino acids in wild-type and mutant proteins to assume folded and unfolded conformations. DUET is an integrated computational approach that utilizes both SDM and mCSM to predict the effect of non-synonymous single-nucleotide polymorphisms on protein stability. Lastly, the I-Mutant webserver is a neural network-based tool for predicting mutation-associated free energy changes. The I-Mutant2.0 tool enables prediction of free energy changes under differing conditions of pH, temperature, neighboring residues, and solvent accessibility. For predicting protein stability, pH 7.0 and temperature at 25 C were applied.

## Results

### Strain frequencies

Antigenic variations among Zika strains were examined by first obtaining the complete sequences of Zika polypeptides

from the NCBI Zika resource<sup>19</sup>. A total of 409 Zika polypeptide sequences were retrieved. Identical polypeptide sequences were removed, resulting in a final total of 257 sequences. Sequences were aligned by MUSCLE using Geneious software, E protein sequences were extracted, and duplicate E protein sequences were removed, resulting in a total of 75 unique sequences (Table 1). Of note, the majority of the 75 unique E protein sequences were represented strains isolated in 2015 and 2016. Sequences from isolates collected in 2017 did not harbor any unique mutations in comparison to sequences from isolates collected in previous years; thus, 2017 sequences were removed after duplicate E protein sequences were removed.

### Phylogeny

A phylogenetic tree of unique E protein sequences was constructed using the maximum-likelihood function in PhyML software, with 100 bootstrap replications (Figure 1). Zika strain accession numbers shown in the phylogenetic tree denote the year of isolation. Notably, E protein sequences from isolates collected in 1968, 2007, 2010, and 2012 clustered in one group, indicating that the associated strains are closely related (Figure 1). However, sequences from strains isolated in 2013 and 2014 exhibited divergence from the sequences of strains isolated in previous years (Figure 1).

### Antigenic epitopes

A number of recent reports describe the isolation of mAbs specific for Zika E protein<sup>23–28</sup>. These antibodies bind preferentially to epitopes located in DII and DIII of the E glycoprotein (Table 2). A total of 7 neutralizing mAbs have been isolated from Zika-virus infected humans, and all of these mAbs bind to discontinuous epitopes of E protein. Of note, ZIKV-117 and ZIKV-19 mAbs recognize epitopes located in DII (Table 2), whereas ZIKV-12 and ZIKV-15 mAbs recognize epitopes located in the FL region, and mAbs ZIKV-Z006, and ZIKV-116 as well as the ZKA 190 mAb recognize epitopes located in DIII. Significant overlap between antigenic epitopes specific for ZIKV-Z006 and ZIKV-116 was observed, as three residues in the epitope recognized by the ZIKV-116 mAb are shared with the epitope recognized by ZIKV-Z006 (Table 2). In addition, the epitope region recognized by the ZKA 190 mAb overlapped with that of the mAb specific for ZIKV-Z006 in two amino acids residues.

A total of 10 B-cell epitopes of Zika E protein were found to elicit humoral antibody responses in vaccinated mice (Table 2). Five of these epitopes were shown to be linear and elicited the production of neutralizing antibodies (Table 2). An additional five discontinuous epitopes have been characterized based on antibodies obtained from vaccinated mice (Table 2). The majority of those epitopes are bound to DIII domain of E.


To identify amino acid substitution mutations occurring in B-cell epitopes, we aligned the sequences of 75 unique E protein amino acids sequences among the 422 pre-epidemic and epidemic Zika strains identified. The sequence of Zika/Nigeria/9/9/1968 was used as a reference, and the E protein sequences were mapped against all of the mAbs from Zika infected humans or

**Table 1. List of unique E protein sequences and their frequency.**

Number	Accession	Sequence Description	Frequency	N-Glycosylation
1	AMR68906	Homo sapiens Nigeria 09/09/1968		-
2	ACD75819	Homo sapiens Micronesia 01/06/2007		154 NDTG
3	AMR39834	Homo sapiens Cambodia 2010	2	154 NDTG
4	AMD61711	Homo sapiens Philippines 09/05/2012		154 NDTG
5	ANO46307	Homo sapiens French Polynesia 11/2013		154 NDTG
6	ANO46309	Homo sapiens French Polynesia 01/2014		154 NDTG
7	AMD61710	Homo sapiens Thailand 19/07/2014		154 NDTG
8	AMK49165	Homo sapiens Brazil 2015		154 NDTG
9	AMK49164	Homo sapiens Brazil 2015		154 NDTG
10	AOC50654	Homo sapiens Honduras 06/01/2015		154 NDTG
11	AMX81917	Homo sapiens Thailand 16/01/2015		154 NDTG
12	ASB32509	Homo sapiens Brazil 13/05/2015	4	154 NDTG
13	ALX35659	Homo sapiens Suriname 02/10/2015		154 NDTG
14	AMC13913	Homo sapiens Guatemala 01/11/2015		154 NDTG
15	AMD16557	Homo sapiens Brazil 30/11/2015		154 NDTG
16	ASU55392	Homo sapiens Colombia 12/2015		154 NDTG
17	ASU55393	Homo sapiens Colombia 12/2015		154 NDTG
18	ASU55394	Homo sapiens Colombia 12/2015		154 NDTG
19	ASU55403	Homo sapiens Colombia 12/2015		154 NDTG
20	ASU55399	Homo sapiens Colombia 12/2015		154 NDTG
21	ASU55411	Homo sapiens Colombia 12/2015		154 NDTG
22	ASU55407	Homo sapiens Colombia 12/2015	3	154 NDTG
23	ASU55396	Homo sapiens Colombia 12/2015		154 NDTG
24	ASU55398	Homo sapiens Colombia 12/2015		154 NDTG
25	ASU55409	Homo sapiens Colombia 12/2015		154 NDTG
26	AMQ48982	Homo sapiens Brazil 29/01/2016		154 NDTG
27	AMQ48986	Homo sapiens USA 02/02/2016		154 NDTG
28	AMK79469	Homo sapiens China 06/02/2016		154 NDTG
29	APC60216	Homo sapiens Mexico 03/03/2016		154 NDTG
30	AOY08538	Homo sapiens Brazil 21/03/2016		154 NDTG
31	AOX49265	Homo sapiens Italy 04/2016	2	154 NDTG
32	AQS26698	Homo sapiens South Korea 04/2016		-
33	AOY08534	Homo sapiens Brazil 05/04/2016	167	154 NDTG
34	ARB07987	Homo sapiens Dominican Republic 07/04/2016 Republic 07/04/2016 07		154 NDTG
35	ARB07941	Homo sapiens Brazil 14/04/2016		-
36	ARB07968	Homo sapiens Brazil 15/04/2016		154 NDTG
37	ARB07988	Homo sapiens Dominican Republic 18/04/2016 Republic 2016/04/18		154 NDTG
38	AQS26816	Homo sapiens Brazil 24/04/2016		154 NDTG

Number	Accession	Sequence Description	Frequency	N-Glycosylation
39	APG56499	Homo sapiens Taiwan 05/2016		154 NDTG
40	ATG29278	Homo sapiens Honduras 10/05/2016		154 NDTG
41	ARB07930	Homo sapiens Honduras 13/05/2016		154 NDTG
42	ATG29285	Homo sapiens Mexico 17/05/2016		154 NDTG
43	ART29823	Homo sapiens Russia 31/05/2016		154 NDTG
44	ARB07996	Homo sapiens Dominican Republic 06/06/2016 r Republic04/07/4 Republic 2016/06/06		154 NDTG
45	ARB07964	Homo sapiens Honduras 07/06/2016		154 NDTG
46	ARB07960	Homo sapiens Honduras 10/06/2016		154 NDTG
47	ARB07931	Homo sapiens Jamaica 13/06/2016		154 NDTG
48	AOY08535	Homo sapiens Dominican Republic 14/06/2016 Republic 2016/06/14		154 NDTG
49	APB03018	Homo sapiens USA 21/06/2016		154 NDTG
50	ARB07974	Homo sapiens Puerto Rico 26/06/2016		154 NDTG
51	ATG29297	Homo sapiens Mexico 05/07/2016		154 NDTG
52	ATG29280	Homo sapiens Mexico 06/07/2016		154 NDTG
53	ATG29301	Homo sapiens Mexico 07/07/2016		154 NDTG
54	ARB07936	Homo sapiens Jamaica 10/07/2016		154 NDTG
55	ATG29267	Homo sapiens Guatemala 21/07/2016	2	154 NDTG
56	APO39231	Homo sapiens USA 29/07/2016		154 NDTG
57	AQX32984	Homo sapiens Honduras 26/08/2016		154 NDTG
58	APH11519	Homo sapiens Singapore 27/08/2016		154 NDTG
59	APH11522	Homo sapiens Singapore 27/08/2016		154 NDTG
60	APH11526	Homo sapiens Singapore 27/08/2016		154 NDTG
61	APH11536	Homo sapiens Singapore 28/08/2016		154 NDTG
62	APH11556	Homo sapiens Singapore 28/08/2016		154 NDTG
63	APH11539	Homo sapiens Singapore 29/08/2016		154 NDTG
64	APH11534	Homo sapiens Singapore 30/08/2016		154 NDTG
65	APH11611	Homo sapiens Thailand 30/08/2016		154 NDTG
66	APH11493	Homo sapiens Singapore 04/09/2016		154 NDTG
67	APH11502	Homo sapiens Singapore 07/09/2016	4	154 NDTG
68	APH11511	Homo sapiens Singapore 13/09/2016		154 NDTG
69	APH11588	Homo sapiens Singapore 15/09/2016		154 NDTG
70	APO39241	Homo sapiens USA 03/10/2016		154 NDTG
71	AQX32988	Homo sapiens Venezuela 19/10/2016		154 NDTG
72	ARK18853	Homo sapiens China 01/11/2016	5	154 NDTG
73	APO08504	Homo sapiens China 03/11/2016		154 NDTG
74	BAX00477	Homo sapiens Japan 22/11/2016		154 NDTG
75	ASU55416	Homo sapiens Colombia 12/2016	2	154 NDTG





**Figure 1. Phylogenetic tree of the unique E protein sequences between the years 1968–2017.** Year 1968 colored (purple), 2007 (yellow), 2010 (cyan), 2012 (green), 2013 (red), 2014 (brown), 2015 (magenta), and 2016 (blue).

vaccinated mice. We then annotated the mutations in Zika E glycoprotein at predefined B-cell epitopes. Only nine Zika strains were found to carry mutations in the predefined B-cell epitopes recognized by mAbs from Zika-virus infected humans. Of note, two amino acids substitutions (R335T) and (D393E) appeared in 2007 (Figure 2A). These amino acids substitutions were retained in all subsequent strains from 2007 to 2016. Interestingly, no unique mutations were observed in predefined B-cell epitopes for isolates collected between 2008 and 2014. However, in 2015, two additional substitutions of alanine residues for threonine residues appeared at amino acid positions 309 and 333 (Figure 2A). These mutations were not retained in subsequently isolated Zika strains, with the sequences quickly reverting to those of previously isolated strains. The greatest number of amino acid substitution mutations occurred in 2016; the majority of the mutations identified in 2016 involved several deletions in specific regions of the predefined B-cell epitopes (Figure 2A). Of note, the Dominican Republic/6/6/2016 strain exhibited significant deletions in B-cell epitopes recognized by ZIKV-Z006 mAb (Figure 2A). Surprisingly, 3 B-cell epitopes

were completely conserved in the pre-epidemic and epidemic strains and indeed have not changed for nearly 50 years (Figure 2A). These epitopes are recognized by the mAbs ZIKV-117, ZIKV-15, and ZIKV-19. Thus, as these mAbs could exhibit cross-reactivity against a wide range of Zika strains, they have potential for use in the development of vaccines and immunotherapeutics targeting Zika (Figure 2A).

Conversely, none of 10 mouse B-cell epitopes were completely conserved among all Zika strains (Figure 2B, Figure 2C). Of note, the number of Zika strains exhibiting variations in the amino acid sequence at predefined antigenic epitopes of the E protein was higher in mAbs characterized in vaccinated mice than in mAbs characterized in infected humans (Figure 2B, Figure 2C). In addition, both the linear and discontinuous epitopes of vaccinated mice exhibited variations beginning in 2014 and continuing in subsequent years (Figure 2B, Figure 2C). The majority of mAbs in vaccinated mice recognized the DIII of E protein, and these epitopes exhibited higher rates of sequence variation than did the mAbs recognizing DII (Figure 2B,

**Table 2.** List of B cell epitopes of Zika E protein mapped with neutralizing antibodies from infected humans and vaccinated mice.

	IEDB ID	Epitope	E Domain	mAb	References
<b>Human Epitopes</b>	605975	D67, Q89, K118	DII	ZIKV-117	23
	605976	T309, E393, K394	DIII	ZIKV-116	23
	605977	W101	FL	ZIKV-15	23
	605978	W101, F108	FL	ZIKV-12	23
	605979	W217, F218, D220, P222	DII	ZIKV-19	23
	628722	Y305, S306, L307, T309, A310, A311, G334, T335, D336, K340, Q350, T351, L352, V391, G392, E393, K394, K395	DIII	ZIKV-Z006	24
	733913	Y305, A333, T335, E370, N371	DIII	ZKA 190	25
<b>Mouse Epitopes Discontinuous</b>	540699	T76, Q77, W101, G102, G104, C105, G106, L107, F108	DII	ZIKV-E-2A10G6	20
	558355	K301, T315, K316, I317, P318, A319, E320, T321, L322, T327, E329, N362, V364, I365, T366, E367, S372, K373, M374, M375, E377	DIII (C-C' loop)	ZV-48	26
	558356	L307, K340, P342, A343, Q344, V347, D348, Q350, T351, L352, T353, P354, L358, D384, Y386	DIII (LR)	ZV-54	26
	558357	L307, K340, P342, A343, Q344, V347, D348, Q350, T351, L352, T353, P354, V355, L358, V391	DIII (C-C' loop)	ZV-64	26
	558358	T309, A310, A311, F312, T313, F314, Q331, Y332, A333, G334, T335, D336, G337, S368, E370, N371, E393, K394, K395, I396, T397	DIII (LR)	ZV-67	26
<b>Mouse Epitopes Linear</b>	745460	D247, A248, H249, A250, K251, R252, Q253, T254, V255, V256, V257, L258, G259, S260, Q261, E262, G263, A264, V265	DII	NA	27
	745469	G383, D384, S385, Y386, I387, V388, I389, G390, V391, G392, D393, K394	DIII	NA	27
	745482	L300, K301, G302, V303, S304, Y305, S306, L307, C308, T309, A310, A311, F312, T313, F314, T315, K316, V317, P318, A319, E320, T321	DIII	NA	27
	753507	L352, T353, P354, V355, G356, R357, L358, I359, T360, A361, N362, P363, V364, I365, T366, E367	DIII	NA	27
	745501	T427, A428, W429, D430, F431, G432, S433, V434, G435, G436, V437, F438, N439, S440, L441, G442, K443	DIII	NA	27



**A**

Description	ZIKV-117	ZIKV-116	ZIKV-15	ZIKV-12	ZIKV-19	ZKA 190	ZIKV-Z006
	605975	605976	605977	605978	605979	733913	628722
AMR68906   Homo sapiens   Nigeria/09/09/1968	D	Q	K	T	D	K	W
ACD75819   Homo sapiens   Micronesia/01/06/2007	Q	K	T	D	K	W	W
AMX81917   Homo sapiens   Thailand/16/01/2015	Q	K	T	D	K	W	W
AMQ48982   Homo sapiens   Brazil/29/01/2016	Q	K	T	D	K	W	W
AMQ48986   Homo sapiens   USA/02/02/2016	Q	K	T	D	K	W	W
ATG29285   Homo sapiens   Mexico/17/05/2016	Q	K	T	D	K	W	W
ARB07996   Homo sapiens   Dominican Republic/06/06/2016	Q	K	T	D	K	W	W
ATG29297   Homo sapiens   Mexico/05/07/2016	Q	K	T	D	K	W	W
APH11522   Homo sapiens   Singapore/27/08/2016	Q	K	T	D	K	W	W

**Figure 2A. B-cell epitopes alignments mapped with human anti-E monoclonal antibodies.** A total of 9 Zika strains are variable at predefined B-cell epitopes during 1968–2017.

**B**

Description	ZIKV-E-2A10G6	ZV-48	ZV-54
	540699	558355	558356
AMR68906   Homo sapiens   Nigeria/09/09/1968	T	T	T
AMD61710   Homo sapiens   Thailand/19/07/2014	Q	Q	Q
AMK49164   Homo sapiens   Brazil/2015	W	W	W
AMX81917   Homo sapiens   Thailand/16/01/2015	G	G	G
ASU55399   Homo sapiens   Colombia/12/2015	C	C	C
AMK79469   Homo sapiens   China/06/02/2016	O	O	O
ATG29285   Homo sapiens   Mexico/17/05/2016	G	G	G
ARB07996   Homo sapiens   Dominican Republic/06/06/2016	L	L	L
ARB07931   Homo sapiens   Jamaica/13/06/2016	K	K	K
ATG29297   Homo sapiens   Mexico/05/07/2016	T	T	T
ARB07936   Homo sapiens   Jamaica/10/07/2016	P	P	P
APO39231   Homo sapiens   USA/29/07/2016	K	K	K
APH11522   Homo sapiens   Singapore/27/08/2016	I	I	I
APH11526   Homo sapiens   Singapore/27/08/2016	I	I	I
APH11536   Homo sapiens   Singapore/28/08/2016	I	I	I
APH11556   Homo sapiens   Singapore/28/08/2016	I	I	I
APO39241   Homo sapiens   USA/03/10/2016	I	I	I
APO80504   Homo sapiens   China/03/11/2016	I	I	I

**Figure 2B. Discontinuous B-cell epitopes alignments mapped with mice anti-E monoclonal antibodies.** A total of 18 Zika strains were variable at predefined B-cell epitopes during 1968–2017.

**C**

Description	745460	745482	753507	745469	745501
	AMR68906   Homo sapiens   Nigeria/09/09/1968	D	A	H	A
AMD61710   Homo sapiens   Thailand/19/07/2014	H	A	K	R	Q
AMK49164   Homo sapiens   Brazil/2015	K	R	Q	T	V
AOC50654   Homo sapiens   Honduras/06/01/2015	R	Q	V	D	Q
AMX81917   Homo sapiens   Thailand/16/01/2015	A	V	D	Q	T
AMD16557   Homo sapiens   Brazil/30/11/2015	K	V	D	Q	T
ASU55399   Homo sapiens   Colombia/12/2015	R	V	D	Q	T
AMQ48986   Homo sapiens   USA/02/02/2016	A	V	D	Q	T
ARB07987   Homo sapiens   Dominican Republic/07/04/2016	K	V	D	Q	T
ARB07996   Homo sapiens   Dominican Republic/06/06/2016	R	V	D	Q	T
ARB07931   Homo sapiens   Jamaica/13/06/2016	A	V	D	Q	T
ARB07974   Homo sapiens   Puerto Rico/26/06/2016	K	V	D	Q	T
ATG29297   Homo sapiens   Mexico/05/07/2016	R	V	D	Q	T
ATG29280   Homo sapiens   Mexico/06/07/2016	S	V	D	Q	T
ARB07936   Homo sapiens   Jamaica/10/07/2016	K	V	D	Q	T
APH11522   Homo sapiens   Singapore/27/08/2016	K	V	D	Q	T
APH11526   Homo sapiens   Singapore/27/08/2016	K	V	D	Q	T
APH11536   Homo sapiens   Singapore/28/08/2016	K	V	D	Q	T
APH11556   Homo sapiens   Singapore/28/08/2016	K	V	D	Q	T
APO39241   Homo sapiens   USA/03/10/2016	K	V	D	Q	T
APO80504   Homo sapiens   China/03/11/2016	K	V	D	Q	T
BAX00477   Homo sapiens   Japan/22/11/2016	K	V	D	Q	T

**Figure 2C. Linear B-cell linear alignments mapped with mice anti-E antibodies.** A total of 20 Zika strains were variable at predefined B-cell epitopes during 1968–2017.

Figure 2C). Of note, the ZIKV-E-2A10G6 mAb binds to a highly conserved discontinuous epitope in which a single amino acid deletion was observed in Zika strain ATG29285[*Homo sapiens*|Mexico|17/05/2016]. Remarkably, discontinuous epitopes bound the ZV-67 mAb exhibited the highest degree of variation in amino acid sequence among all the Zika B-cell epitopes examined (Figure 2B). Sequence variations were also observed in all of the Zika E protein linear epitopes (Figure 2C).

### E protein homology modeling

The recently solved E protein structure of Zika enabled us to construct a homology model of various E protein sequences. Amino acid substitutions in B-cell epitopes were also annotated on the 3D structure of the E protein. The majority of mutations in the E protein were found to be located within DIII, whereas the B-cell epitopes in DII were highly conserved (Figure 3). Zika strain *Homo sapiens*/French Polynesia/11/13 did not harbor any additional mutations in B-cell epitopes compared with Zika strain *Homo sapiens*/Micronesia/01/06/07 (Supplementary Figure 1).


It is known that *N*-glycosylation can mask antigenic epitopes. However, as the glycosylation site in the Zika E protein is located remotely from the predefined B-cell epitopes, glycosylation does not mask the B-cell antigenic epitopes (Figure 3). This is consistent with reports of glycosylation in E protein of WNV and JEV<sup>18</sup>. A recent report demonstrated that glycosylation at 154 is critical for Zika infection of both mammalian and mosquito hosts<sup>17</sup>. Our analyses indicate that antigenic changes

occur less frequently in Zika strains (Figure 3) and suggest that highly effective neutralizing Zika vaccines and immunotherapies for treating infections with known Zika strains are possible. Consequently, monitoring antigenic changes in E proteins over time would be useful for evaluating the cross-neutralizing potential of Zika vaccines against newly mutated strains.

### Mutational stability

Mutation stability was carried out to predict the effects of non-synonymous variants on the stability of E protein and antibody binding. Here, we analyzed the stability of monomeric E protein upon substitutional mutations. Amino acids substitutions can affect the strength, number of interaction, and protein folding and thus increase or decrease binding affinity. To investigate the effect of amino acids substitutions at antigenic epitopes on the stability of E protein and antibody binding of E, 4 prediction tools for mutational stability were selected.

We predicted the stability of B-cell epitope mutations using the 3D structure of Zika E proteins. In both the T309A and T335A substitutions, a polar threonine residue was substituted with a hydrophobic alanine residue. No change in hydrophobicity with the V391I mutation or change in charge with the D393E were observed. In the R335T mutation, a basic residue was substituted with an aromatic residue. Overall, these suggest that defined substitutions in the E glycoprotein are potentially destabilizing. However, these mutations had moderate destabilizing effect, as the  $\Delta\Delta G$  values ranged between -0.3 and -0.7 kcal/mol (Table 3).



**Figure 3. Comparison of B-cell epitopes of monomeric E between the years 1968, 2007, 2010, 2015, and 2016.** Homology models of E were built from PDB: 5GZN chain A from strains of following E sequences: AMR68906| *Homo sapiens* |Nigeria|09/09/1968, ACD75819| *Homo sapiens* |Micronesia|01/06/2007, ANO46307| *Homo sapiens*/French Polynesia/11/2013, AMX81917/*Homo sapiens*/Thailand/16/01/2015, and AMQ48986 | *Homo sapiens* |USA|02/02/2016. Color blue color represents amino acids conservation at B-cell epitopes and color pink represents amino acids substitutions. Yellow label represent N-glycosylation potential of E.

**Table 3. Mutational stability prediction of substituted amino acids at B-cell epitopes of E.**

Mutations	mCSM	Effect	SDM	Effect	DUET	Effect	I-Mutant2.0	Effect
T309A	- 0.464 Kcal/mol	Destabilizing	0.12 Kcal/mol	Stabilizing	-0.22 Kcal/mol	Destabilizing	-0.15 Kcal/mol	Decreased stability
T335A	- 0.596 Kcal/mol	Destabilizing	0.12 Kcal/mol	Stabilizing	-0.337 Kcal/mol	Destabilizing	0.33 Kcal/mol	Increased stability
R335T	- 0.304 Kcal/mol	Destabilizing	-0.38 Kcal/mol	Destabilizing	-0.173 Kcal/mol	Destabilizing	NA	NA
V391I	- 0.375 Kcal/mol	Destabilizing	0.08	Stabilizing	-0.022	Destabilizing	-0.25 Kcal/mol	Decreased stability
D393E	- 0.38 Kcal/mol	Destabilizing	0.06 Kcal/mol	Stabilizing	-0.149 Kcal/mol	Destabilizing	NA	NA

## Discussion

Attempts to control the spread of Zika virus via mosquito control have met with limited success. Indeed, within the past 3 years, a Zika pandemic occurred. There is a significant gap in knowledge regarding immunogenic cross-reactivity between Zika strains, even six decades after the first human infection was reported. Bioinformatics approaches can play vital roles in identifying rapidly evolving amino acid residues and thereby facilitate precise mapping of key residues that drive antigenic escape in response to the generation of host neutralizing antibodies. In the present study, we evaluated conserved versus rapidly evolving antigenic regions in predefined B-cell epitopes of the Zika E protein in pre-epidemic and epidemic periods.

The finger-like DII of the Zika E protein contains a FL that is inserted into the endosomal membrane as a result of pH-dependent conformational changes<sup>14</sup>. The FL is located within the beta-sheet structure in the terminal region of DII and contains a highly conserved hydrophobic peptide that triggers the structural changes required for fusion processes under conditions of low pH<sup>15</sup>. Our analysis demonstrated that B-cell epitopes in DII of Zika E protein are highly conserved. mAbs ZIKV-117, ZIKV-15, and ZIKV-19 are bound to the highly conserved region of DII and are therefore attractive candidates in the design of Zika vaccines and immunotherapeutics.

The immunoglobulin-like DIII of the Zika E protein contains receptor-binding sites and plays an essential role in attachment and fusion of the virus to host cells<sup>11,12</sup>. Importantly, DIII reportedly induces the production of type-specific neutralizing antibodies<sup>26</sup>, as mAbs isolated from patients infected with either Zika or dengue are highly specific. In the present study, we found that epitopes within E protein DIII vary greatly within Zika strains.

While dengue is considered as a single serotype, it is characterized by four distinct serotypes. The antibody-dependent enhancement (ADE) hypothesis holds that cross-reactive antibodies generated as a result of previous infections with heterologous flaviviruses can enhance the infectivity of other viruses<sup>42,43</sup>. Infection with the same serotype elicits a protective immune response, but re-infection with a different serotype can lead to serious disease<sup>42,43</sup>. Previous studies demonstrated that mAbs isolated

from patients infected with dengue virus cross-react with Zika virus<sup>44-47</sup>.

Similarly, mAbs isolated from Zika patients directed against E protein DII cross-react with dengue<sup>44,48</sup>, indicating possible increased risk of ADE. Furthermore, another study demonstrated that dengue-virus derived mAbs also cross-react with Zika with high potency<sup>20</sup>. Those mAbs are bound to quaternary epitopes, which include the site of interaction of E protein dimer with PrM during virus maturation<sup>20</sup>. In contrast, most mAbs directed against DIII of Zika E protein do not cross-react with dengue<sup>44</sup>.

In the present study, we compared mAbs of Zika E protein elicited in cases of Zika-virus infected humans versus mAbs induced by Zika vaccination in mice and identified several conserved epitope footprints. The conserved E protein epitopes could be useful in research aimed at developing vaccines that elicit the production of antibodies that provide protection against Zika strains but do not cross-react with dengue. For example, immunization with a peptide cocktail of antigenic DIII epitopes might provide broad protection against a variety of Zika strains yet demonstrate no cross-reactivity with dengue, thus eliminating the possibility of ADE associated with the anti-Zika antibodies.

## Data availability

Zika protein sequences data can be found at the [NCBI Zika resource](#).

Zika B-cell antigenic epitopes can be found at [Immune Epitope Database \(IEDB\)](#).

## Grant information

The research was supported by Deanship of Scientific Research at Imam Abdulrahman Bin Faisal University [DSR 2017-376-IRMC].


*The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

## Acknowledgment

We would like to thank Arwa Alghamdi from College of Pharmacy at IAU who assisted in the research.



## Supplementary material



**Supplementary Figure 1. Ramachandran plot analysis of 3D structure of monomeric E.** Homology model for sequences of [Nigeria|09/09/1968, ACD75819] Homo sapiens [Micronesia|01/06/2007, ANO46307] Homo sapiens/French Polynesia/11/2013, AMX81917/Homo sapiens/Thailand/16/01/2015, and AMQ48986 | Homo sapiens |USA|02/02/2016 were verified.

## References

- Kuno G, Chang GJ: **Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses.** *Arch Virol.* 2007; **152**(4): 687–696.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lindenbach BD, Rice CM: **Molecular biology of flaviviruses.** *Adv Virus Res.* 2003; **59**: 23–61.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dick GW, Kitchen SF, Haddock AJ: **Zika virus. I. Isolations and serological specificity.** *Trans R Soc Trop Med Hyg.* 1952; **46**(5): 509–520.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Macnamara FN: **Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria.** *Trans R Soc Trop Med Hyg.* 1954; **48**(2): 139–145.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Duffy MR, Chen TH, Hancock WT, *et al.*: **Zika virus outbreak on Yap Island, Federated States of Micronesia.** *N Engl J Med.* 2009; **360**(24): 2536–2543.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Cao-Lormeau VM, Roche C, Teissier A, *et al.*: **Zika virus, French polynesia, South pacific, 2013.** *Emerg Infect Dis.* 2014; **20**(6): 1085–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zanluca C, Melo VC, Mosimann AL, *et al.*: **First report of autochthonous transmission of Zika virus in Brazil.** *Mem Inst Oswaldo Cruz.* 2015; **110**(4): 569–572.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Metsky HC, Matranga CB, Wohl S, *et al.*: **Zika virus evolution and spread in the Americas.** *Nature.* 2017; **546**(7658): 411–415.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Apte-Sengupta S, Sirohi D, Kuhn RJ: **Coupling of replication and assembly in flaviviruses.** *Curr Opin Virol.* 2014; **9**: 134–142.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zhang Y, Corver J, Chipman PR, *et al.*: **Structures of immature flavivirus particles.** *EMBO J.* 2003; **22**(11): 2604–2613.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

11. Stadler K, Allison SL, Schlich J, *et al.*: **Proteolytic activation of tick-borne encephalitis virus by furin.** *J Virol.* 1997; 71(11): 8475–8481.  
[PubMed Abstract](#) | [Free Full Text](#)
12. Yu IM, Zhang W, Holdaway HA, *et al.*: **Structure of the immature dengue virus at low pH primes proteolytic maturation.** *Science.* 2008; 319(5871): 1834–1837.  
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Dai L, Song J, Lu X, *et al.*: **Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody.** *Cell Host Microbe.* 2016; 19(5): 696–704.  
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Modis Y, Ogata S, Clements D, *et al.*: **Structure of the dengue virus envelope protein after membrane fusion.** *Nature.* 2004; 427(6972): 313–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Rey FA, Heinz FX, Mandl C, *et al.*: **The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution.** *Nature.* 1995; 375(6529): 291–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Kostyuchenko VA, Lim EX, Zhang S, *et al.*: **Structure of the thermally stable Zika virus.** *Nature.* 2016; 533(7603): 425–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Bressanelli S, Stiasny K, Allison SL, *et al.*: **Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation.** *EMBO J.* 2004; 23(4): 728–738.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Vaughan AT, Roghanian A, Cragg MS: **B cells—masters of the immuniverse.** *Int J Biochem Cell Biol.* 2011; 43(3): 280–285.  
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Heinz FX, Auer G, Stiasny K, *et al.*: **The interactions of the flavivirus envelope proteins: implications for virus entry and release.** *Arch Virol Suppl.* 1994; 9: 339–348.  
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, *et al.*: **Structural basis of potent Zika-dengue virus antibody cross-neutralization.** *Nature.* 2016; 536(7614): 48–53.  
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Paul LM, Carlin ER, Jenkins MM, *et al.*: **Dengue virus antibodies enhance Zika virus infection.** *Clin Transl Immunology.* 2016; 5(12): e117.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Xu X, Vaughan K, Weiskopf D, *et al.*: **Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus Species.** *PLoS Curr.* 2016; 8: pii: ecurrents.outbreaks.9aa2e1fb61b032f58a098773008c4b.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Sapparapu G, Fernandez E, Kose N, *et al.*: **Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice.** *Nature.* 2016; 540(7633): 443–447.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Robbiani DF, Bozzacco L, Keefe JR, *et al.*: **Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.** *Cell.* 2017; 169(4): 597–609.e11.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Wang J, Bardelli M, Espinosa DA, *et al.*: **A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential.** *Cell.* 2017; 171(1): 229–241.e15.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Zhao H, Fernandez E, Dowd KA, *et al.*: **Structural Basis of Zika Virus-Specific Antibody Protection.** *Cell.* 2016; 166(4): 1016–1027.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Basu R, Zhai L, Contreras A, *et al.*: **Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells.** *Vaccine.* 2018; 36(10): 1256–1264.  
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Hatcher EL, Zhdanov SA, Bao Y, *et al.*: **Virus Variation Resource - Improved response to emergent viral outbreaks.** *Nucleic Acids Res.* 2017; 45(D1): D482–D490.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Kearse M, Moir R, Wilson A, *et al.*: **Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data.** *Bioinformatics.* 2012; 28(12): 1647–1649.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Guindon S, Dufayard JF, Lefort V, *et al.*: **New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0.** *Syst Biol.* 2010; 59(3): 307–321.  
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Biasini M, Bienert S, Waterhouse A, *et al.*: **SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information.** *Nucleic Acids Res.* 2014; 42(Web Server issue): W252–W258.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Laskowski RA, MacArthur MW, Moss DS, *et al.*: **Procheck - A Program to Check the Stereochemical Quality of Protein Structures.** *J App Cryst.* 1993; 26: 283–291.  
[Publisher Full Text](#)
33. Chen VB, Arendall WB 3rd, Headd JJ, *et al.*: **MolProbity: all-atom structure validation for macromolecular crystallography.** *Acta Crystallogr D Biol Crystallogr.* 2010; 66(Pt 1): 12–21.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Xu D, Zhang Y: **Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization.** *Biophys J.* 2011; 101(10): 2525–2534.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Vita R, Overton JA, Greenbaum JA, *et al.*: **The immune epitope database (IEDB) 3.0.** *Nucleic Acids Res.* 2015; 43(Database issue): D405–D412.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Pettersen EF, Goddard TD, Huang CC, *et al.*: **UCSF Chimera—a visualization system for exploratory research and analysis.** *J Comput Chem.* 2004; 25(13): 1605–1612.  
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Gupta R, Jung E, Brunak S: **Prediction of N-Glycosylation Sites in Human Proteins.** 2004; 46: 203–206.
38. Pires DE, Ascher DB, Blundell TL: **mCSM: predicting the effects of mutations in proteins using graph-based signatures.** *Bioinformatics.* 2014; 30(3): 335–342.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Worth CL, Preissner R, Blundell TL: **SDM—a server for predicting effects of mutations on protein stability and malfunction.** *Nucleic Acids Res.* 2011; 39(Web Server issue): W215–W222.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Pires DE, Ascher DB, Blundell TL: **DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach.** *Nucleic Acids Res.* 2014; 42(Web Server issue): W314–W319.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Capriotti E, Fariselli P, Casadio R: **I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure.** *Nucleic Acids Res.* 2005; 33(Web Server issue): W306–W310.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Kiks SC, Nisalak A, Brandt WE, *et al.*: **Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever.** *Am J Trop Med Hyg.* 1989; 40(4): 444–451.  
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Lobigs M, Diamond MS: **Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.** *Expert Rev Vaccines.* 2012; 11(2): 177–187.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Stettler K, Beltramello M, Espinosa DA, *et al.*: **Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.** *Science.* 2016; 353(6301): 823–826.  
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Priyamvada L, Quicke KM, Hudson WH, *et al.*: **Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus.** *Proc Natl Acad Sci U S A.* 2016; 113(28): 7852–7857.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Swanstrom JA, Plante JA, Plante KS, *et al.*: **Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.** *mBio.* 2016; 7(4): pii: e01123-16.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Dejnirattisai W, Supasa P, Wongwiwat W, *et al.*: **Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus.** *Nat Immunol.* 2016; 17(9): 1102–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Kawiecki AB, Christofferson RC: **Zika Virus-Induced Antibody Response Enhances Dengue Virus Serotype 2 Replication *In Vitro*.** *J Infect Dis.* 2016; 214(9): 1357–1360.  
[PubMed Abstract](#) | [Publisher Full Text](#)

# Open Peer Review

Current Peer Review Status:  

---

## Version 2

Reviewer Report 01 July 2019

<https://doi.org/10.5256/f1000research.21556.r50488>

© 2019 Jia M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



### Meirong Jia

Roy J. Carver Department of Biochemistry, Biophysics & Molecular Biology, Iowa State University, Ames, IA, USA

Good for indexing.

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

## Version 1

Reviewer Report 21 May 2019

<https://doi.org/10.5256/f1000research.17985.r42684>

© 2019 Joshi S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



### Sunil K Joshi

Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL, USA

Authors described *in-silico* methods to delineate the data which are particularly important due to high mutation rates by RNA viruses which can generate mutations, that enable them to evade the host immune system. Authors emphasized the structural stability of E protein, which is a key factor for antibody binding. The bioinformatic analysis of B cell epitopes of Zika is very important study in terms of developing effective vaccine and may be also in cross-protection against other similar viruses.

In the present study, the authors extracted all of the available E protein sequences for Zika isolates



obtained from 1968 to 2017 and constructed three-dimensional (3D) structures of E proteins from various Zika strains using homology modelling. Further the authors investigated the patterns and conservation of E protein B-cell epitopes and assessed their structural stability upon mutation. The authors did meticulous data analysis and discussed very thoroughly.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

I cannot comment. A qualified statistician is required.

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Innate Immunity, Infectious diseases, Vaccinology

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 06 November 2018

<https://doi.org/10.5256/f1000research.17985.r39301>

© 2018 Jia M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Meirong Jia**

Roy J. Carver Department of Biochemistry, Biophysics & Molecular Biology, Iowa State University, Ames, IA, USA

Summary: Zika virus is still a big threat to human health, and E protein is its major structural determinant of immunity. The identification of B-cell epitopes of Zika E protein is crucial for the development of vaccines and immunotherapeutics. Here, the authors conducted systematic bioinformatics analyses of Zika strains isolated between 1968 and 2017, they've found conservative epitopes between Zika strains, which could be attractive targets for treating against diverse Zika strains. The research report is generally sound and the finding is scientifically

valuable, which would provide guidance for later research in Zika vaccine development. Thus, I would recommend the indexing of this work in F1000Research.

The followings are some suggestions and comments that might help to make the report more suitable for indexing:

1. In the 'Introduction' part, for the 2<sup>nd</sup> paragraph, "After maturation, pr is released from the host cell" is that "PrM" being released instead?
2. In 'Table 2', the first row, should "mAB" be "mAb"?
3. In the 'Abstract', for the 'Results' part, "Our analyses indicate that epitopes recognized by human mAbsZIKV-117, ZIKV-15, and ZIKV-119 Should be "ZIKV-19", please correct it. Also, since there is mutation as shown in 'Fig 2B' other than the strict conservation pattern in 'Fig 2A', please rewrite the claim that "ZIKV-E-2A10G6 mAb derived from immunized mice was highly conserved across Zika strains".
4. In the 'Results', for E protein homology modelling, the 2<sup>nd</sup> paragraph, "Glycosylation does not mask the B-cell epitope epitopes" should be "antigenic epitopes?"
5. In the 'Method' part, for 'Mapping of antigenic epitopes', "Potential N-glycosylation sites were defined by the sequence Asp/X/Ser/Thr, where X represents any amino acid except Pro. A threshold of >0.5 suggested an N-glycosylated residue." Please further explain what values >0.5 would suggest an N-glycosylated residue.
6. The authors described in the 'Methods' that "The I-Mutant2.0 tool enables prediction of free energy changes under differing conditions of pH, temperature, neighboring residues, and solvent accessibility." For the data shown in 'Table 3', what conditions did authors apply to conduct the prediction?
7. In the 'Results', the last paragraph, "Overall, these suggest that defined substitutions in the E glycoprotein are potentially destabilizing." Could the authors further discuss what the consequence or effects of destabilization has on virus infection since authors said that the structural stability of E protein is a key factor for antibody binding.
8. In the 'Discussion' part, the authors claimed that "The conserved E protein epitopes could be useful in research aimed at developing vaccines that elicit the production of antibodies that provide protection against Zika strains but do not cross-react with dengue." Yet from the manuscript, it seems that no conserved epitopes in DIII has been identified. If so, authors might need to rewrite the last part of the discussion.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**

I cannot comment. A qualified statistician is required.

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 11 Jun 2019

**Iman Almansour**, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

We thank Dr.Jia for the careful reading of the manuscript and the constructive remarks.

Response to general comments:

1. Corrections has been made.
2. Corrections has been made.
3. Yes, thank you for pointing this out. Corrections were made.
4. Yes, we are sorry for the unintended mistake. Corrections were made.
5. Explanation has been made.
6. pH 7.0 and temperature at 25 C were applied. The details were added in the method section.
7. In the revised document, we further explained the effect of mutations on protein stability and protein binding (Results section, mutation stability, first paragraph).
8. In the discussion section, we have explained that immunization with a cocktail of antigenic DIII epitopes might provide broad protection against a variety of Zika strains.

**Competing Interests:** No competing interests were disclosed.

---

## Comments on this article

Version 1

Reader Comment 30 Jan 2019

**Million Abraha**, University of Bern, Switzerland

I have read the whole article and i find it to be really interesting.

**Competing Interests:** No competing interests were disclosed.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**